Vivek Ramaswamy acquired the rights to a failed Alzheimer's drug very cheaply, reworked the failed trials to show improvement, and hyped the potential on Jim Cramer's investment show.
The IPO raised the most ever for a biotech company, and the stock skyrocketed, allowing Ramaswamy and his inner circle to cash out their shares. But when phase 3 trials were conducted, the drug flopped again, causing the stock to plummet 99% in one day.
Vivek Ramaswamy enriched himself while costing small investors their life savings (must-watch 5-min video) | Boing Boing
This new TikTok video investigates how Vivek Ramaswamy acquired the rights to a failed Alzheimer’s drug very cheaply, reworked the failed trials to show improvement with help from his mother,…


